News
PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid ...
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC) Median Overall Survival of 17.3 months in ...
Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data ...
How the co-design of a practical guide to support nursing practice related to long Covid can enhance patient safety and ...
9h
MotorTrend on MSNNot Dead Yet: Are Reports of the Demise of Polestar Premature?Some higher-volume Polestars coming this year might revive Polestar's clouded prospects, says CEO Thomas Ingenlath.
While the state Department of Education has made trainings and tools available, researchers say it needs to do more to help ...
BioCryst will present four abstracts at the meeting: Impact of Berotralstat on Quality of Life among Patients with Hereditary ...
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and ...
8h
TipRanks on MSNAllarity announces first patient enrolled in Phase 2 trial of stenoparibTherapeutics announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the ...
Get ready for a chilling ride through the depths of Netflix's horror genre! From spine-tingling suspense to outright terror, ...
BASEL, Switzerland I June 1, 2025 I Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results